Amgen, AstraZeneca announce top-line results from WAYPOINT trial

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps. The trial demonstrated patients treated with Tezspire had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. The safety profile and tolerability of Tezspire in the trial were consistent with the known profile of the medicine. Waypoint was a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tezspire administered subcutaneously in adults with severe CRSwNP. Participants in the trial were symptomatic despite treatment with standard of care, intranasal corticosteroids, or INCS. CRSwNP is a complex inflammatory condition characterized by persistent inflammation of the nasal mucosa accompanied by soft tissue growths, called nasal polyps, and is most commonly treated with INCS and surgery, if required.